Day: September 29, 2020

Basel, Switzerland, September 29, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated a phase 2 expansion study with its tumor checkpoint controller, lisavanbulin, in patients with recurrent glioblastoma multiforme (GBM), whose tumor has tested positive for the potential response-predictive biomarker EB1 (end-binding protein 1).1Glioblastoma is the most common type of primary brain cancer and one of the most lethal types of cancer.2 In the open-label study, patients will receive once daily oral lisavanbulin. To identify patients with EB1-positive glioblastoma, a tissue screening program has been implemented using a CE-marked immunohistochemistry clinical trial assay developed for the lisavanbulin program.Dr. Marc Engelhardt, Chief Medical Officer, said: “The initiation of the phase 2 study is an important...

Basel, 29. September 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie eine Phase-2- Erweiterungsstudie mit ihrem Tumor-Checkpoint-Controller Lisavanbulin initiiert hat. In dieser Studie wird Lisavanbulin bei Patienten mit rezidivierendem Glioblastom (Glioblastoma multiforme, GBM) untersucht, deren Tumor positiv auf EB1 (engl. End-binding protein 1) getestet wurde, einem potenziellen Biomarker für das Ansprechen auf den Wirkstoffkandidaten.1Glioblastom ist die häufigste Form primärer maligner Hirntumore und zählt zu den Krebsarten mit der höchsten Sterblichkeit.2 In der Open-label-Studie wird Lisavanbulin einmal täglich oral verabreicht. Zur Identifizierung von Patienten mit EB1-positivem Glioblastomgewebe wurde ein Screening-Programm implementiert und ein CE-gekennzeichnetes immunohistochemisches Nachweisverfahren...

AB Ignitis Grupė, (hereinafter – Ignitis Grupė or „the Company”) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 900 000 000 EUR; ISIN codes XS1646530565; XS1853999313; XS2177349912.The Company received questions from former minority shareholders of Energijos Skirstymo Operatorius AB (hereinafter – ESO) and Ignitis Gamyba AB (hereinafter – Ignitis Gamyba) regarding the pre-emptive right to acquire shares of Ignitis grupė. In order to ensure that all former minority shareholders are equally informed, the Company publishes detailed information on the pre-emptive right to acquire shares of Ignitis grupė.I am a former minority shareholder of ESO and/or Ignitis Gamyba and have the pre-emptive rights to the shares of Ignitis grupė. How can I invest...

AB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra  „Ignitis grupė“ išleistų obligacijų nominali vertė 900 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313; XS2177349912.Bendrovė sulaukė buvusių smulkiųjų AB „Energijos skirstymo operatorius“ (ESO) ir AB „Ignitis gamybos“ (GEN) akcininkų klausimų dėl pirmumo teisės įsigyti „Ignitis grupės“ akcijų. Siekdama užtikrinti, kad visi buvę smulkieji akcininkai būtų vienodai informuoti, Bendrovė skelbia detalizuotą informaciją apie pirmumo teisę įsigyti „Ignitis grupės“ akcijų.Žemiau pateikiami atsakymai į dažniausiai užduodamus klausimus apie šį procesą.Aš esu buvęs ESO ir/arba „Ignitis gamybos“ smulkusis akcininkas, kuris turi pirmumo teisę į „Ignitis grupės“ akcijas. Kaip galiu investuoti...

In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2 infection in Syrian golden hamsters.At day 5, STI-2020 at 500 µg reduced virus load in hamster lungs to undetectable levels in 100% of animals tested, whereas STI-1499 at 2,000 µg reduced virus load below the detection limit in 60% of animals tested and showed a 10-fold reduction in the remaining 40% of animals.SAN DIEGO, Sept. 28, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) released preclinical data reporting on COVI-GUARD™ (STI-1499) and COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 as...

TORONTO, Sept. 28, 2020 (GLOBE NEWSWIRE) — Unigold Inc. Corp. (the “Company”) (TSXV: UGD) (FSE: UGD1) (OTCQX: UGDIF) announces that the Board of Directors has approved the grant of stock options (“Options”) to directors, officers, employees and consultants of the Company allowing for the acquisition of an aggregate of up to 6,000,000 common shares of the Company (“Shares”). An aggregate of 4,500,000 Options were issued with an exercise price of $0.34 per Share, with an expiry date of September 28, 2021. The remaining 1,500,000 Options were issued with an exercise price of $0.34 per Share and an expiry date of September 28, 2022. The grants of Options were issued pursuant and subject to the terms and conditions of the Company’s stock incentive plan and TSX Venture Exchange policies.About Unigold...

Orphazyme A/SCompany announcement                                                                                       No. 56/2020                                                                                                         Company Registration No. 32266355      · Orphazyme A/S has today received notification regarding the beginning of the stabilization periodCopenhagen, Denmark, September 29, 2020 – With reference to company announcement no. 55/2020 dated September 29, 2020 regarding the pricing of the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share (the “Ordinary Shares”) of Orphazyme, on the Nasdaq Global Select Market in the United States under the symbol “ORPH” (the “U.S....

SHANGHAI, China, Sept. 28, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that an Independent Monitoring Committee (IDMC) determined that the randomized, double-blind, placebo-controlled, international multi-center Phase III study JUPITER-02 at the interim analysis had met its pre-specified primary endpoint. The results of the study showed that Toripalimab in combination with Gemcitabine/Cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) significantly extended the progression-free survival than the current standard treatment of Gemcitabine/Cisplatin. The Company will submit biologic license application...

Orphazyme A/SCompany announcement                                                                                           No. 55/2020                                                                                                          Company Registration No. 32266355As announced on September 21, 2020, Orphazyme commenced an initial public offering of American Depositary Shares (“ADSs”) in the United States, and commenced a concurrent private placement of ordinary shares in Europe Today, September 29, 2020 (CET), Orphazyme announces the pricing of the global offering at a price per new ordinary share of DKK 70.1844, corresponding to a price of USD 11.00 per ADS The aggregate gross proceeds from the global offering will amount to approximately DKK 534,534,637 (USD 83,777,606 using a DKK/USD exchange rate of 6.3804) (assuming no exercise...

ATLANTA, Sept. 28, 2020 (GLOBE NEWSWIRE) — Mueller Water Products, Inc. (NYSE: MWA) will participate in the 2020 RBC Capital Markets Future of Water Virtual Conference on Tuesday, September 29, 2020. The panel discussion is currently scheduled to take place at 8:40 a.m. ET. A live webcast, audio replay and any changes to the presentation timing will be available on the Investor Relations section of the Company’s website www.muellerwaterproducts.com. A replay of the webcast will be available for approximately 90 days.About Mueller Water Products, Inc.Mueller Water Products, Inc. (NYSE: MWA) is a leading manufacturer and marketer of products and services used in the transmission, distribution and measurement of water in North America. Our broad product and service portfolio includes engineered valves, fire hydrants, pipe connection...